Although osimertinib, an irreversible third-generation EGFR-TKI, has been recommended by the National Comprehensive Cancer Network guidelines as a preferred first-line treatment for patients with EGFR-sensitizing mutation advanced NSCLC, first- or second-generation EGFR-TKIs are still an important first-line choice in some parts of the world due to cost and lower overall survival (OS) benefit of osimertinib in subgroups of the Asian population or patients with the 21L858R point mutation compared to first-generation EGFR-TKIs gefitinib and erlotinib observed in the FLAURA study (7). This evidence concerns the gene EGFR and non-small cell lung carcinoma.